Argent Biopharma Limited has released a press release.
Publication of Peer Reviewed Glioblastoma Research
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Long COVID study Results
- Pause in Trading
- Operations Update
- Appointment of UK Corporate Advisor and Company Update
- TGA advertising Infringement Notice
Later from Argent Biopharma
- US$1,000,000 ArtemiC order delivered to US partner, AMC
- Completion of CimetrA Efficacy Pre-clinical Trial
- $800,000 of funding received through Mercer Facility
- Internal Costs Review Completed and Board Change
- Results of CimetrA bioanalytics pre-clinal trial
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma